These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 26387747)

  • 21. Serum pigment epithelium-derived factor is elevated in women with polycystic ovary syndrome and correlates with insulin resistance.
    Yang S; Li Q; Zhong L; Song Y; Tian B; Cheng Q; Qing H; Xia W; Luo M; Mei M
    J Clin Endocrinol Metab; 2011 Mar; 96(3):831-6. PubMed ID: 21209034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
    Kebapcilar L; Taner CE; Kebapcilar AG; Alacacioglu A; Sari I
    Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome.
    Tarkun I; Dikmen E; Cetinarslan B; Cantürk Z
    Eur Cytokine Netw; 2010 Dec; 21(4):272-7. PubMed ID: 21126943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome.
    Tan BK; Chen J; Hu J; Amar O; Mattu HS; Adya R; Patel V; Ramanjaneya M; Lehnert H; Randeva HS
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1891-900. PubMed ID: 24152681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
    Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
    J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
    Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations.
    Luque-Ramírez M; Escobar-Morreale HF
    Horm Metab Res; 2010 Oct; 42(11):815-20. PubMed ID: 20730705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
    Agarwal N; Rice SP; Bolusani H; Luzio SD; Dunseath G; Ludgate M; Rees DA
    J Clin Endocrinol Metab; 2010 Feb; 95(2):722-30. PubMed ID: 19996308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations--introductory report.
    Marciniak A; Nawrocka-Rutkowska J; Brodowska A; Sienkiewicz R; Szydłowska I; Starczewski A
    Folia Histochem Cytobiol; 2009; 47(2):323-8. PubMed ID: 19995720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
    Cappelli V; Di Sabatino A; Musacchio MC; De Leo V
    Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
    Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
    Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin.
    Sun X; Wu X; Zhou Y; Yu X; Zhang W
    Med Sci Monit; 2015 Aug; 21():2547-52. PubMed ID: 26314870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homocysteine and ghrelin link with polcystic ovary syndrome in relation to obesity.
    Altuğ Şen T; Köken R; Narcı A; Yılmazer M
    J Pediatr Adolesc Gynecol; 2011 Aug; 24(4):211-7. PubMed ID: 21458334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.
    Ziaee A; Oveisi S; Abedini A; Hashemipour S; Karimzadeh T; Ghorbani A
    Acta Med Indones; 2012 Jan; 44(1):16-22. PubMed ID: 22451180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.